Geoffrey I. Shapiro, MD, PhD
Although the roles of cyclin-dependent kinases (CDKs) were established more than 20 years ago, early anticancer inhibitors in the class resulted in high toxicity levels. Now, a new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer.
Figure. Relationship of KRAS Signaling to CDKs2
Mutations in KRAS
are among the earliest and most important drivers of disease progression. When KRAS
is mutated, several downstream pathways, such as the MEK/ ERK and PI3K/AKT signaling pathways, become constitutively activated.
... to read the full story